PBYI News and Press, Puma Biotechnology Inc From 07/06/21

MONTREAL, July 06, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) in combination with capecitabine for the treatment of...

Dose escalation of NERLYNX therapy demonstrated improved management and prevention of Grade 3 diarrhea Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a labeling supplement to the U.S. ...

Puma Biotechnology ([[PBYI]] +3.2%) presents results from the Phase III ExteNET trial assessing the impact of neratinib treatment duration on overall survival ((OS)) in patients with early stage HER2-positive breast cancer at the virtual 2021 ASCO Annual Meeting. Among patients who compl...

Puma Biotechnology (PBYI) presents interim results from the Phase II SUMMIT basket trial, assessing the efficacy of neratinib in patients with EGFR exon 18-mutant non-small cell lung cancer ((NSCLC)), including patients with central nervous system ((CNS)) involvement, at the virtual 2021 ASCO...

Neratinib efficacy evidenced in patients with EGFR exon 18-mutant non-small cell lung cancer and CNS involvement Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented interim results from the Phase II SUMMIT basket trial, assessing the efficacy of n...

Dose escalation of neratinib lowers the frequency of severe diarrhea and improves overall tolerability in patients with HER2-positive early stage breast cancer Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented results at the virtual 2021 ASCO An...

Results show improved outcomes in overall survival in patients with HER2-positive early stage breast cancer who received ≥ 11 months of treatment with neratinib Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase III ...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of three abstracts on neratinib for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8, 2021. Puma will present three posters with audio reco...

Puma Biotechnology, Inc. (PBYI) Q1 2021 Earnings Conference Call May 06, 2021, 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Founder, Chairman, President, CEO & Secretary Jeff Ludwig - Chief Commercial Officer Maximo Nougues - CFO & Principal ...